Subcutaneous Frusemide in patients with heart failure

Phase 4

Recruiting

• Conditions: Decompensated Heart Failure; Cardiovascular - Coronary heart disease; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12612000477820
• Lead Sponsor: Auckland City Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Decompensated heart failure as meaured by 2 or more of the following - increasing weight, shortness of breath, orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales, elevated JVP, peripheral and/or abdominal oedema

Exclusion Criteria

Cardiovascular instability, inotropes, and/or BiPAP, Creatinine >250umol/

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
et urine volume voided[24 hours];Urine sodium concentration[24 hours];Time to first void[Measured from commencement of infusion]

Secondary Outcome Measures

Name	Time	Method
Site reactions[4 hourly until end of treatment period at 48 hours- using Organisational Wide Phlebitis Scale <br>(RCN,2005)];creatinine- serum assay[Daily for 4 days];length of hospital stay, number of days out of hospital[data linkage to medical records to 3 months post discharge]